Historical Valuation
Psyence Biomedical Ltd (PBM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Psyence Biomedical Ltd (PBM) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.77
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Psyence Biomedical Ltd (PBM) has a current Price-to-Book (P/B) ratio of 0.13. Compared to its 3-year average P/B ratio of -26.24 , the current P/B ratio is approximately -100.48% higher. Relative to its 5-year average P/B ratio of -21.33, the current P/B ratio is about -100.59% higher. Psyence Biomedical Ltd (PBM) has a Forward Free Cash Flow (FCF) yield of approximately -284.21%. Compared to its 3-year average FCF yield of -90.51%, the current FCF yield is approximately 214.00% lower. Relative to its 5-year average FCF yield of -73.66% , the current FCF yield is about 285.85% lower.
P/B
Median3y
-26.24
Median5y
-21.33
FCF Yield
Median3y
-90.51
Median5y
-73.66
Competitors Valuation Multiple
AI Analysis for PBM
The average P/S ratio for PBM competitors is 0.00, providing a benchmark for relative valuation. Psyence Biomedical Ltd Corp (PBM.O) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for PBM
1Y
3Y
5Y
Market capitalization of PBM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PBM in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PBM currently overvalued or undervalued?
Psyence Biomedical Ltd (PBM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Psyence Biomedical Ltd (PBM) is between to according to relative valuation methord.
What is Psyence Biomedical Ltd (PBM) fair value?
PBM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Psyence Biomedical Ltd (PBM) is between to according to relative valuation methord.
How does PBM's valuation metrics compare to the industry average?
The average P/S ratio for PBM's competitors is 0.00, providing a benchmark for relative valuation. Psyence Biomedical Ltd Corp (PBM) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Psyence Biomedical Ltd (PBM) as of Jan 09 2026?
As of Jan 09 2026, Psyence Biomedical Ltd (PBM) has a P/B ratio of 0.13. This indicates that the market values PBM at 0.13 times its book value.
What is the current FCF Yield for Psyence Biomedical Ltd (PBM) as of Jan 09 2026?
As of Jan 09 2026, Psyence Biomedical Ltd (PBM) has a FCF Yield of -284.21%. This means that for every dollar of Psyence Biomedical Ltd’s market capitalization, the company generates -284.21 cents in free cash flow.
What is the current Forward P/E ratio for Psyence Biomedical Ltd (PBM) as of Jan 09 2026?
As of Jan 09 2026, Psyence Biomedical Ltd (PBM) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Psyence Biomedical Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Psyence Biomedical Ltd (PBM) as of Jan 09 2026?
As of Jan 09 2026, Psyence Biomedical Ltd (PBM) has a Forward P/S ratio of 0.00. This means the market is valuing PBM at $0.00 for every dollar of expected revenue over the next 12 months.